Related coverage linked through entity extraction aliases.
Apr 25, 2026
Generic semaglutide launched in India as Novo Nordisk’s patent expired, with prices starting below Rs 1,300 a month. Doctors and companies said device quality, cold chains and patient support will also shape sales.
Mar 24, 2026
Seven Indian pharmaceutical companies have launched generic semaglutide drugs at prices 70-80% lower than Novo Nordisk's Ozempic following patent expiration. Novo Nordisk has cut prices by 37% to maintain market share as competition intensifies in India's growing weight-loss drug market.
Feb 17, 2026
Indian pharmaceutical companies Sun Pharma and Glenmark are integrating AI into drug discovery to reduce development timelines and costs. Global pharma AI investment reached $6.93 billion last year and is projected to hit $16.5 billion by 2034.
